atebimetinib | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5 results for “atebimetinib”

Trials

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

510 participants · First posted May 1, 2026

News

Immuneering Doses First Patient in Phase III MAPKeeper 301 Trial of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer

Immuneering Receives FDA and EMA Alignment for Phase 3 Atebimetinib Trial in First-Line Pancreatic Cancer

Immuneering Partners with Lilly for Phase 2 NSCLC Combination Trial Testing Dual MAPK Pathway Blockade